Court Ruling Could Invalidate Numerous Genome Patents

A UK court decision invalidating a patent for a nucleotide and amino acid sequence of the human genome looks set to raise the bar for protecting intellectual property (IP). In the UK's first case relating to the validity of a gene sequence, the court ruled in favour of Eli Lilly after it found that Human Genome Sciences (HGS)' patent on neutrokine-α lacked industrial application, had insufficient evidence and was

To read the full article, please sign in or take a free trial.